BioCryst Pharmaceuticals | BCRX - 债务利息支出

股票价格

9.41

每天变化

-0.15 -1.57%

每月一次

1.18%

每年

33.66%

Q2 预测

9.30

金融业

USD

USD 514.16M

现金及等价物

USD 335.91M

USD 9.52M

USD 404.35M

USD 196.07M

USD 828.6M

股息收益率

0

USD 260.39M

USD 51.7M

536

EPS每股收益

USD 1.17

股本和储备

USD -119.15M

USD 153.05M

债务利息支出

USD 14.14M

USD -0.13

USD 428.67M

USD 1.96B

USD 245.85M

USD 146.17M

USD 260.39M

普通股股本

USD 213.06M

6.06

USD 248.02M

USD 406.56M

销售和管理费用

USD 95.78M

USD 5.4M

贸易债权人

USD 15.83M

应收帐款人

USD 106.82M

	债务利息支出	更改		日
Alnylam Pharmaceuticals	USD 129.34M		84.94M	2025-12
BioCryst Pharmaceuticals	USD 14.14M		5.53M	2025-12
Chugai Pharma	JPY 95M		260M	2025-12
Daiichi Sankyo	JPY 2.16B		1.33B	2025-12
DBV Technologies	USD 461K		323.71K	2025-03
Enanta Pharmaceuticals	USD 1.96M		620K	2024-12
Gilead Sciences	USD 255M		1000K	2025-12
GlaxoSmithKline	GBP 188M		21M	2025-12
Glaxosmithkline	GBP 177.95M		6.05M	2025-09
Incyte	USD 582K		10K	2025-12
Ionis Pharmaceuticals	USD 18M		0	2025-12
Karyopharm Therapeutics	USD 12.62M		1.24M	2025-12
Neurocrine Biosciences	USD 1.1M		0	2024-03
Novavax	USD 5.82M		342K	2025-12
PTC Therapeutics	USD 50.58M		2.59B	2025-12
Regeneron Pharmaceuticals	USD 12.2M		7.1M	2025-12
Roche Holding	CHF 304M		7.5M	2025-06
Sarepta Therapeutics	USD 7.56M		2.33M	2025-09
Ultragenyx Pharmaceutical	USD 19M		4.85M	2025-12
Vertex Pharmaceuticals	USD 3.3M		0	2025-12